GlassScriptPhysician profile
Alexander M Yeh
NPI 1275533010
$3,165.25
in general payments reported to CMS, 2019-2025
28 companies · $17.93 in 2025
The $17.93 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2021: $253 · 2022: $110 · 2023: $67.80 · 2024: $1,776 · 2025: $17.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,132 · Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,132.48 |
| Food and Beverage | $729.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,758.55 | 2024 | Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System |
| Varian Medical Systems, INC. | $235.02 | 2019-2021 | |
| Novocure INC. | $149.36 | 2019 | |
| Puma Biotechnology, INC. | $125.00 | 2021 | |
| Lilly USA, LLC | $123.92 | 2019-2022 | |
| Eisai INC. | $98.05 | 2019-2023 | |
| Tersera Therapeutics LLC | $81.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.48 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $78.46 | 2019 | |
| Merck Sharp & Dohme LLC | $45.86 | 2019 | |
| Amgen INC. | $43.90 | 2019 | |
| Janssen Biotech, INC. | $33.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $33.53 | 2019 | |
| Incyte Corporation | $29.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.21 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $26.21 | 2019 | |
| Daiichi Sankyo INC. | $24.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.65 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $19.15 | 2019 | |
| Tris Pharma INC | $17.93 | 2025 | Dyanavel Xr |
| Exelixis INC. | $16.44 | 2019 | |
| Emd Serono, INC. | $16.33 | 2019 | |
| Genzyme Corporation | $16.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.14 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.21 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.12 | 2019 | |
| Pfizer INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.